BioCentury
ARTICLE | Company News

Actinium, Fred Hutchinson deal

July 16, 2012 7:00 AM UTC

The center granted Actinium worldwide rights to develop and commercialize BC8. The mAb against CD45 is in development to target and eradicate cancerous and other white blood cells in preparation for ...